Thonzylamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Thonzylamine
Accession Number
DB11235
Type
Small Molecule
Groups
Approved
Description

Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with Clofedanol or Phenylephrine for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

Structure
Thumb
Synonyms
  • neohetramine
Product Ingredients
IngredientUNIICASInChI Key
Thonzylamine hydrochloride6K9YKD48Y463-56-9HRYJPHOTGFERGT-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Nasopen PEThonzylamine hydrochloride (50 mg/15mL) + Phenylephrine hydrochloride (10 mg/15mL)LiquidOralGm Pharmaceuticals2012-10-03Not applicableUs
Poly Hist PDThonzylamine hydrochloride (6.25 mg/mL) + Chlophedianol hydrochloride (6.25 mg/mL)LiquidOralPoly Pharmaceuticals2013-07-01Not applicableUs
Poly-Hist DMThonzylamine hydrochloride (25 mg/5mL) + Dextromethorphan hydrobromide (10 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL)LiquidOralPoly Pharmaceuticals2013-06-22Not applicableUs
TexaClear Kids Sinus ReliefThonzylamine hydrochloride (50 mg/30mL) + Phenylephrine hydrochloride (5 mg/30mL)LiquidOralGm Pharmaceuticals2015-06-15Not applicableUs
Categories
UNII
R79646H5Z8
CAS number
91-85-0
Weight
Average: 286.379
Monoisotopic: 286.179361344
Chemical Formula
C16H22N4O
InChI Key
GULNIHOSWFYMRN-UHFFFAOYSA-N
InChI
InChI=1S/C16H22N4O/c1-19(2)11-12-20(16-17-9-4-10-18-16)13-14-5-7-15(21-3)8-6-14/h4-10H,11-13H2,1-3H3
IUPAC Name
N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyrimidin-2-amine
SMILES
COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Thonzylamine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Thonzylamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Thonzylamine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Thonzylamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Thonzylamine.Experimental, Illicit
AmphetamineAmphetamine may decrease the sedative activities of Thonzylamine.Approved, Illicit, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Thonzylamine.Approved, Illicit
Benzylpenicilloyl PolylysineThonzylamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Thonzylamine.Approved, Investigational
ChlorphentermineChlorphentermine may decrease the sedative activities of Thonzylamine.Illicit, Withdrawn
DextroamphetamineDextroamphetamine may decrease the sedative activities of Thonzylamine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative activities of Thonzylamine.Approved, Illicit
GepefrineGepefrine may decrease the sedative activities of Thonzylamine.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Thonzylamine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Thonzylamine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Thonzylamine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Thonzylamine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Thonzylamine.Investigational
MephentermineMephentermine may decrease the sedative activities of Thonzylamine.Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Thonzylamine.Approved, Illicit
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Thonzylamine.Experimental
MidomafetamineMidomafetamine may decrease the sedative activities of Thonzylamine.Experimental, Illicit, Investigational
MMDAMMDA may decrease the sedative activities of Thonzylamine.Experimental, Illicit
PhenterminePhentermine may decrease the sedative activities of Thonzylamine.Approved, Illicit
PseudoephedrinePseudoephedrine may decrease the sedative activities of Thonzylamine.Approved
RitobegronRitobegron may decrease the sedative activities of Thonzylamine.Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5457
PubChem Substance
347827947
ChemSpider
5258
ChEBI
104017
ChEMBL
CHEMBL1623738
ATC Codes
R01AC06 — ThonzylamineD04AA01 — ThonzylamineR06AC06 — Thonzylamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.733 mg/mLALOGPS
logP2.4ALOGPS
logP2.42ChemAxon
logS-2.6ALOGPS
pKa (Strongest Basic)8.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area41.49 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity86.19 m3·mol-1ChemAxon
Polarizability32.42 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-05fr-9720000000-8a7d4d036feab1e4ee54
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Anisoles
Direct Parent
Anisoles
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Dialkylarylamines / Benzylamines / Aminopyrimidines and derivatives / Alkyl aryl ethers / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Phenoxy compound / Anisole / Benzylamine / Methoxybenzene / Dialkylarylamine / Alkyl aryl ether / Aminopyrimidine / Monocyclic benzene moiety / Pyrimidine / Heteroaromatic compound
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on December 03, 2015 09:51 / Updated on December 01, 2017 17:25